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Abstract
Transforming growth factor-beta (TGFb) is a secreted polypeptide that plays essential roles in cellular development and
homeostasis. Although mechanisms of TGFb-induced responses have been characterized, our understanding of TGFb
signaling remains incomplete. Here, we uncover a novel function for the protein kinase NDR1 (nuclear Dbf2-related 1) in
TGFb responses. Using an immunopurification approach, we find that NDR1 associates with SnoN, a key component of TGFb
signaling. Knockdown of NDR1 by RNA interference promotes the ability of TGFb to induce transcription and cell cycle arrest
in NMuMG mammary epithelial cells. Conversely, expression of NDR1 represses TGFb-induced transcription and inhibits the
ability of TGFb to induce cell cycle arrest in NMuMG cells. Mechanistically, we find that NDR1 acts in a kinase-dependent
manner to suppress the ability of TGFb to induce the phosphorylation and consequent nuclear accumulation of Smad2,
which is critical for TGFb-induced transcription and responses. Strikingly, we also find that TGFb reciprocally regulates NDR1,
whereby TGFb triggers the degradation of NDR1 protein. Collectively, our findings define a novel and intimate link between
the protein kinase NDR1 and TGFb signaling. NDR1 suppresses TGFb-induced transcription and cell cycle arrest, and
counteracting NDR1’s negative regulation, TGFb signaling induces the downregulation of NDR1 protein. These findings
advance our understanding of TGFb signaling, with important implications in development and tumorigenesis.
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Introduction
The transforming growth factor beta (TGFb) family of cytokines
regulates a wide array of biological responses that are critical for
proper development and homeostasis [1,2,3,4]. Deregulation of
TGFb-mediated responses contributes to the pathogenesis of
diverse disease processes from pulmonary and renal fibrosis to
cancer [5,6,7,8,9]. A widely studied and key biological effect of
TGFb is the inhibition of hematopoietic and epithelial cell
proliferation [10,11,12,13], which has important consequences in
cancer biology. Several types of carcinomas acquire resistance to
TGFb-induced cell cycle arrest, leading to uncontrolled cell
proliferation [10,11,12,13,14].
TGFb ligands form heteromeric complexes with type I and II
transmembrane TGFb receptors, which have intrinsic serine/
threonine kinase activities [15,16,17,18,19]. The type II kinase
transphosphorylates the type I receptor in a glycine-serine rich
motif, thereby stimulating the type I kinase activity [20,21,22].
The Smad family of intracellular signaling proteins is critical for
transducing TGFb signals from the cell surface to the nucleus to
regulate gene expression and consequent cellular processes
[7,23,24]. In particular, the TGFb-stimulated type I receptors
associate and phosphorylate the receptor-regulated Smad (R-
Smad) proteins Smad2 and Smad3 on the C-terminal two serine
residues in the SSXS motif [23,24,25,26]. The phosphorylated R-
Smads then form a heteromeric complex with the common
partner Smad4, and the R-Smad/Smad4 complex accumulates in
the nucleus and binds to specific binding elements within
promoters of TGFb responsive genes [26,27,28]. The R-Smad/
Smad4 complex acts together with other proteins to induce or
repress transcription of responsive genes [29,30,31].
The transcriptional protein SnoN has emerged as a key
regulator of TGFb signaling and responses [32,33,34,35]. SnoN
associates with R-Smad2/3 and Smad4 and thereby regulates
TGFb-induced transcription [36,37,38]. SnoN activates or
represses TGFb-induced transcription, leading to divergent
biological responses in a cell type- or context-dependent manner
[33,34,39,40]. The critical role of SnoN in TGFb signaling
suggests that identifying novel SnoN-associating proteins should
enhance our understanding of TGFb responses.
NDR1 is a member of the evolutionary conserved NDR
(nuclear Dbf2-related) family of serine-threonine kinases that form
a subgroup of AGC kinases [41]. NDR1 and the closely related
family member NDR2 regulate critical cellular processes including
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e67178cell proliferation, apoptosis and differentiation [42,43,44,45,46].
The expression of NDR kinases is deregulated in carcinomas
including breast, lung and prostate cancer [47,48]. Interestingly,
NDR kinases have been proposed to harbor positive or negative
roles in tumorigenesis [47,48]. Whether these kinases regulate
specific signaling pathways has remained largely unexplored [48].
Here, we identify NDR1 as a novel SnoN-interacting protein.
We find that NDR1 inhibits TGFb-induced transcription and cell
cycle arrest. NDR1 inhibits Smad2 phosphorylation, providing the
basis for NDR1 regulation of TGFb responses. Remarkably,
TGFb reciprocally promotes the degradation of NDR1, thereby
providing a counterbalance to NDR1-inhibition of TGFb
signaling. Collectively, our findings point to a novel and intimate
link between the protein kinase NDR1 and TGFb signaling, with
profound effects on the regulation of gene expression and cell
proliferation.
Results
NDR1 Associates with the TGFb Signaling Protein SnoN
To gain new insights into the signaling mechanisms that control
TGFb responses, we focused on identifying proteins that interact
with SnoN, a key component in TGFb signaling. We used a
tandem affinity purification (TAP) approach to immunopurify
SnoN in human HaCaT keratinocytes, in which we stably
expressed the double epitope-tagged version of SnoN (FLAG,
HA-SnoN). To identify true SnoN associated proteins, we used
cells expressing epitope-tagged SnoN at levels equivalent to those
of endogenous SnoN (Figure 1A). Interestingly, stable expression
of SnoN reduced the level of endogenous SnoN in these cells,
further normalizing the level of SnoN between SnoN-expressing
and control vector-transfected cells (Figure 1A, compare endog-
enous SnoN in lane 1 and exogenous SnoN in lane 3). Exposure of
HaCaT cells to TGFb led to the downregulation of endogenous as
well as stably expressed SnoN, suggesting that TGFb signaling
behaves normally in HaCaT cells expressing epitope-tagged SnoN
[37,38,49,50]. We performed tandem affinity purification (TAP)
by sequential FLAG and HA immunoprecipitation of lysates of
epitope-tagged SnoN-expressing HaCaT cells and control HaCaT
cells followed by mass spectrometry of immunocomplexes [51,52].
SnoN and known SnoN-interacting proteins including Ski and
Smad4 were immunopurified from SnoN-expressing cells, con-
firming the validity of the purification procedure (Table 1). We
also identified novel SnoN-interacting proteins (Table 1). Among
these proteins, we focused on the protein kinase NDR1 (also
known as STK38).
NDR1 and its close relative NDR2 regulate several biological
processes including cell proliferation, apoptosis and differentiation
[42,43,44,45,46]. However, whether these kinases regulate specific
growth factor signaling pathways has remained incompletely
understood. Therefore, we further characterized the interaction of
NDR1 with the TGFb signaling protein SnoN. In co-immuno-
precipitation assays, we confirmed that SnoN and NDR1 formed a
complex (Figure 1B, C). We next used the fusion of NDR1 or
SnoN with the Renilla luciferase (Rluc) protein to assess the
interaction of endogenous SnoN or endogenous NDR1, respec-
tively, using Renilla luciferase activity as the readout [53]. We
found that endogenous NDR1 robustly interacted with Rluc-SnoN
(Figure S1A). Likewise, endogenous SnoN strongly interacted with
Rluc-NDR1 (Figure S1B). Consistent with these results, endoge-
nous NDR1 formed a complex with endogenous SnoN in the
absence or presence of TGFb in 293T cells (Figure S1C).
Together, these data suggest that NDR1 associates with SnoN in
epithelial cells.
To gain further insight and evidence for the specificity of the
SnoN-NDR1 association, we mapped the structural determinants
of SnoN that are required for its interaction with NDR1
(Figure 1D). We used a series of Rluc-SnoN mutants in
coimmunoprecipitation assays to enable quantitative assessment
of the effect of mutations of SnoN on its interaction with expressed
NDR1 in 293T cells. Removal of the N-terminal 96 amino acids
did not affect SnoN’s association with NDR1 (Figure 1E).
Consistent with these results, the N-terminal 96 amino acids of
SnoN failed to associate with NDR1. Interestingly, we found that
deletion of amino acid residues 366–684 or 1–366 decreased
significantly the ability of SnoN to interact with NDR1 (Figure 1E).
We also identified the regions in NDR1 that specify its
association with SnoN (Figure 1F). We used the Rluc-NDR1
fusion and its mutants in these experiments. Deletion of the N-
terminal 82 amino acid residues reduced the ability of NDR1 to
associate with SnoN (Figure 1G). Interestingly, deletion of the C-
terminal regulatory region alone or together with the N-terminal
domain dramatically increased the ability of NDR1 to coimmu-
noprecipitate with SnoN (Figure 1G). Together, these data suggest
that a region within the kinase domain specifies the association of
NDR1 with SnoN, and the C-terminal regulatory region may
interfere with the NDR1-SnoN interaction.
NDR1 Regulates TGFb-dependent Transcription
The finding that NDR1 associates with SnoN raised the
important question of whether NDR1 regulates TGFb signaling.
The plasminogen activator inhibitor 1 (PAI-1) is a TGFb-
responsive immediate early gene that has been linked to the
control of cell proliferation [40,54,55,56]. We characterized the
role of NDR1 in TGFb-induced transcription employing the
widely used 3TP-luciferase reporter gene containing TGFb-
responsive promoter elements of the PAI-1 gene [56]. We first
determined the effect of inhibition of endogenous NDR1 on
TGFb-induced transcription. We used RNA interference (RNAi)
to induce knockdown of endogenous NDR1 in epithelial cells.
Two short hairpin RNAs (shRNAs) targeting distinct regions of
NDR1 mRNA induced efficient knockdown of NDR1 protein in
293T cells (Figure S2A). Importantly, in reporter assays, knock-
down of NDR1 using the two shRNAs singly or in combination
significantly enhanced the ability of TGFb to induce expression of
the 3TP-luciferase reporter gene in HaCaT keratinocytes
(Figure 2A). Knockdown of NDR1 in NMuMG mammary
epithelial cells with expression of NDR1 shRNAs also increased
TGFb-induced 3TP-luciferase-reporter gene expression
(Figure 2B). In complementary reporter assays, expression of
NDR1 reduced in a dose-dependent manner the ability of TGFb
to induce expression of the 3TP-luciferase gene in NMuMG cells
(Figure S2B and Figure 2C). Similarly, NDR1 repressed the ability
of TGFb to induce the expression of the 3TP-luciferase reporter
gene in HaCaT cells (Figure 2D). Thus, based on knockdown and
gain of function analyses, we conclude that NDR1 inhibits the
ability of TGFb to induce transcription.
We next characterized the role of NDR1 in the regulation of
TGFb-induced expression of the endogenous PAI-1 gene. As
expected, TGFb stimulation of control-transfected NMuMG cells
increased the abundance of endogenous PAI-1 mRNA as assessed
by quantitative real time PCR. Knockdown of endogenous NDR1
in NMuMG cells significantly enhanced the ability of TGFb to
increase the abundance of PAI-1 mRNA (Figure 3A). We also
measured the ability of TGFb to induce PAI-1 expression in
NMuMG cells stably expressing wild type NDR1 (WT) or a
kinase-inactive version of NDR1 in which Lysine 118 was mutated
to arginine (KR) (Fig. 3B). The expression of wild type NDR1
NDR1 and TGFb Signaling Are Functionally Linked
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cells (Figure 3C). In contrast, the kinase-inactive NDR1 enhanced
the ability of TGFb to increase the abundance of PAI-1 mRNA
(Figure 3C). These data suggest that the kinase-inactive NDR1
enhanced TGFb-induced PAI-1 gene expression by acting in a
dominant negative fashion to block the ability of endogenous
NDR1 to antagonize TGFb-induced transcription. Together,
Figure 1. NDR1 is a novel SnoN-interacting protein. A. Lysates of untreated or TGFb-treated HaCaT cells expressing FLAG, HA-SnoN or control
vector were immunoblotted with the SnoN or actin antibody. TGFb similarly reduced the abundance of endogenous and exogenous SnoN in HaCaT
cells. B. Lysates of 293T expressing MYC-SnoN alone or together with HA-NDR1 were subjected to immunoprecipitation with the HA antibody
followed by immunoblotting with the SnoN or HA antibody. Total lysates were also subjected to immunoblotting with the SnoN or actin antibody,
the latter to serve as a loading control. C. Lysates of 293T cells expressing HA-NDR1 alone or together with MYC-SnoN were subjected to
immunoprecipitation with the SnoN antibody followed by immunoblotting with the HA or SnoN antibody. Lysates were also immunoblotted with
the HA or actin antibody. NDR1 formed a complex with SnoN. D. A schematic diagram showing the wild type (amino acid (aa) 1–684) and four
deletion mutants of SnoN. The dotted area represents the ski/sno/dac (DACH) domain, the shaded area the SAND domain, and the striped areas the
helical dimerization domains [33]. E. Lysates of 293T cells expressing Rluc in fusion with wild type or a series of SnoN mutants, as shown in D, alone or
together with HA-NDR1 were subjected to immunoprecipitation with the HA antibody followed by luciferase assays to determine the levels of Rluc-
SnoN fusion proteins in the NDR1 immunoprecipitates. Aliquots of cell lysates were also assayed for luciferase activity as a measure of Rluc-SnoN
expression. The expression of HA-NDR1 in aliquots of immunoprecipitates (10%) and cell lysates was confirmed by immunoblotting using the HA
antibody (data not shown). NDR1-associated Rluc-SnoN luciferase activity was normalized to Rluc-SnoN and NDR1 expression. Data are presented as
the mean+SEM (n=4) of NDR1-associated Rluc activity relative to Rluc activity associated with NDR1 in the case of the wild type Rluc-SnoN fusion
protein. F. A schematic diagram showing the wild type (aa1–465) and three deletion mutants of NDR1. The dotted area represents the N-terminal
regulatory domain, the shaded area the kinase domain, and the striped area the C-terminal regulatory domain. G. Lysates of 293T cells expressing
Rluc in fusion with wild type or a series of NDR1 mutants, as in F, alone or together with MYC-SnoN, were subjected to immunoprecipitation using
the MYC or SnoN antibody. Immunoprecipitates and cell lysates were subjected to luciferase assays, SnoN immunoblotting (Data not shown), and
data analyses as described in E. Data are presented as the mean+SEM (n=7) of SnoN-associated Rluc activity expressed relative to SnoN-associated
Rluc activity in the case of wild type NDR1-Rluc. *, or *** indicates significant difference as compared to wild type SnoN-Rluc (E) or NDR1-Rluc (G) at
p,0.05 or p,0.001, respectively (ANOVA).
doi:10.1371/journal.pone.0067178.g001
NDR1 and TGFb Signaling Are Functionally Linked
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e67178these data suggest that NDR1 acts in a kinase-dependent manner
to negatively regulate TGFb-induced transcription.
NDR1 Antagonizes TGFb-induced Cell Cycle Arrest
The finding that NDR1 inhibits TGFb-induced gene expression
led us to ask whether NDR1 might also impact biological processes
regulated by TGFb. NMuMG cells undergo growth arrest in
response to TGFb stimulation [57]. We analyzed the growth rate
curves of NMuMG cells stably expressing wild type NDR1 or
kinase-inactive NDR1 protein (KR). Cells were plated and left
untreated or incubated with TGFb and counted after one, two or
three days (Figure 4A, B). As expected, TGFb reduced the
population growth of control-transfected cells (Figure 4A, B).
However, expression of wild type but not the kinase-inactive
NDR1 significantly inhibited the ability of TGFb to suppress the
population growth of NMuMG cells (Figure 4A, B). These data
suggest that NDR1 impairs TGFb-induced cell cycle arrest in a
kinase-dependent manner. NDR1 similarly opposed TGFb
suppression of population growth of NMuMG cells when we
employed automated cell counts using the Cellomics KSR
instrument whereby NMuMG cells were labeled with the DNA
dye bisbenzimide (Hoechst) (Figure S3A). To determine if NDR1
regulates the ability of TGFb to control cell proliferation, we
performed BrdU incorporation assays (Figure 4C). As expected,
TGFb markedly reduced the ratio of BrdU-labeled cells,
suggesting that TGFb induces cell cycle arrest in NMuMG cells
(Figure 4D). The expression of wild type NDR1, but not kinase-
inactive NDR1, opposed TGFb-suppression of BrdU incorpora-
tion in NMuMG cells (Figure 4C, D).
In complementary studies, we found that knockdown of NDR1
enhanced the potency of TGFb to induce 50% reduction in the
population growth of NMuMG cells (EC50) (Figure 4E, F and
Figure S3B, C). Interestingly, knockdown of NDR1 together with
knockdown of the closely related protein NDR2 further enhanced
the potency of TGFb to induce cell cycle arrest in NMuMG cells
(Figure 4E, F, Figure S3C). Collectively, our data suggest that
NDR antagonizes the ability of TGFb to inhibit cell proliferation.
NDR1 Suppresses TGFb-dependent Smad2
Phosphorylation
The ability of NDR1 to oppose TGFb-dependent transcription
and cell cycle arrest raised the question of the mechanism by
which NDR1 exerts this effect. TGFb-dependent phosphorylation
and consequent nuclear accumulation of the receptor-regulated
Smad proteins mediate TGFb-induced transcription and biolog-
ical responses. We, therefore, determined the effect of NDR1 on
the phosphorylation and nuclear accumulation of Smad2 in
NMuMG cells upon exposure to TGFb. As expected, TGFb
robustly increased the phosphorylation of Smad2 (Figure 5A, B).
Strikingly, we found that wild type NDR1 substantially reduced
the ability of TGFb to induce Smad2 phosphorylation in
NMuMG cells (Figure 5). Consistent with these results, wild type
NDR1 suppressed TGFb-induced accumulation of Smad2 in the
nucleus in NMuMG cells (Figure S4). By contrast to wild type
NDR1, expression of the kinase-inactive NDR1 (KR) enhanced
TGFb-induced phosphorylation and nuclear accumulation of
Smad2 in NMuMG cells (Fig. 5 and Fig. S4). Together, these data
suggest that NDR1 inhibits the ability of TGFb to trigger the
phosphorylation and consequent nuclear accumulation of Smad2
and thereby impairs TGFb-induced transcription.
TGFb Signaling Induces NDR1 Degradation
The identification of NDR1 as a negative regulator of TGFb-
induced transcription and cell cycle arrest raised the important
question of whether TGFb signaling might in turn influence
NDR1. We characterized the effect of TGFb on the abundance of
endogenous NDR1 in NMuMG cells. Remarkably, we found that
TGFb stimulation reduced the steady-state levels of NDR1
(Figure 6A, B). Incubation of cells with the TGFb-type I kinase
inhibitor SB431542 (TbRI-KI) restored the abundance of NDR1
protein in TGFb-treated cells (Figure 6A, B). Using quantitative
real-time RT-PCR analyses, we found that TGFb did not reduce
and instead increased the abundance of NDR1 mRNA, suggesting
that TGFb-induced downregulation of NDR1 protein is not due to
changes in NDR1 gene expression (Figure 6C).
Table 1. Mass spectrometry data of SnoN-interacting proteins in HaCaT cells.
Identified protein
a,b gi number Mass Score
c Number of peptides matched Ion score range
Gel slice 1
SnoN 4885599 76955 137 10 7–69
RBM10 12644371 103396 80 4 6–63
Ski 4506967 79955 64 5 21–49
Gel slice 2
SnoN 4885599 76955 214 19 8–68
Skb1Hs/PRMT5
d 232410 72740 161 12 2–82
STK38/NDR1 6005814 54155 115 9 17–52
PTP1B
d 4505995 52609 106 8 4–53
Smad4 4885457 60401 104 12 5–62
a-tubulin 340021 50120 87 3 17–68
Gel Slice 3
No significant hits
aIdentified proteins represent peptides only present in the SnoN-expressing samples, and not in the control cells.
bTrypsin, immunoglobulin and keratin are considered contaminants and are omitted from this list.
conly identified proteins with a score of $50 are shown here.
dThese identified proteins were also present in the control cells, but the number of peptides matched and overall score was much lower in the control cells than in the
SnoN-expressing samples.
doi:10.1371/journal.pone.0067178.t001
NDR1 and TGFb Signaling Are Functionally Linked
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e67178We next considered the possibility that the downregulation in
NDR1 protein in response to TGFb might result from the
increased turnover of NDR1 protein. We measured the rate of
NDR1 protein turnover in NMuMG cells treated for different
times with the protein synthesis inhibitor cycloheximide in the
absence (2) or presence (+) of TGFb (Figure 6D, E). We found
that the half-life of NDR1 in control cells was greater than 16 h,
suggesting that NDR1 is a relatively stable protein. Stimulation of
cells with TGFb reduced the half-life of NDR1 to approximately
8 h, suggesting that TGFb increased the turnover of NDR1
(Figure 6D, E). To further explore the decrease in steady-state
levels of NDR1 by long-term activation of TGFb signaling
(Figure 6A, B), we assessed NDR1 turnover rates in cells that were
left untreated or pretreated with TGFb for 24 h prior to the time-
course treatment of cycloheximide. Interestingly, we found that
pretreatment of cells with TGFb led to eight-fold reduction in the
half-life of NDR1, suggesting that prolonged TGFb treatment
induced substantial degradation of NDR1 (Figure 6F, G). Using
in vivo ubiquitination assays, we found that NDR1 was conjugated
with ubiquitin in 293T cells (Fig. 6H and Figure S5) [49].
Importantly, expression of a constitutively active TGFb type I
receptor, which activates the Smad signaling pathway in the
absence of TGFb addition [21], robustly stimulated the ubiqui-
tination of NDR1 in cells (Figure 6H and Figure S5A). We also
found that exposure of 293T cells to the proteasome inhibitor
MG132 suppressed the ability of TGFb to reduce the abundance
of NDR1 (Figure 6I and Figure S5B). Together, these data suggest
that TGFb signaling induces NDR1 ubiquitination and its
Figure. 2. NDR1 inhibits TGFb-induced transcription. A. Lysates of untreated or TGFb-treated HaCaT cells transfected with the TGFb-
responsive 3TP-Firefly luciferase reporter and CMV-Renilla-luciferase reporter, as a transfection efficiency control, together with the control RNAi
vector (2), or NDR1 RNAi NDR1i-1, NDR1i-2 plasmid alone or together, were subjected to dual luciferase assays. Data are presented as the mean+SEM
(n=4) of normalized-3TP-luciferase activity expressed relative to that of the untreated control. B. Lysates of NMuMG cells transfected with reporters
as in A together with the control RNAi plasmid or the NDR1i-2 plasmid, and analyzed as in A. Data are presented as the mean+SEM (n=3) of luciferase
activity expressed relative to the untreated control. C. Lysates of untreated or TGFb-treated NMuMG cells transfected with reporters as in A, together
with a control vector (2) or increasing concentrations of an NDR1 expression plasmid, were subjected to dual luciferase assays and data analysis as in
A. D. Lysates of untreated or TGFb-treated HaCaT cells transfected as described for NMuMG cells in C except for using the CMV-b-galactosidase
expression plasmid as a transfection efficiency reporter, were subjected to luciferase and b-galactosidase assays. For each experiment, luciferase
activity was normalized as in A. Data in C and D are presented as the mean+SEM (n=5) of 3TP-luciferase activity expressed relative to the untreated
control. *, **, or *** indicates significant difference from the TGFb-treated control at p,0.05, p,0.01, or p,0.001, respectively (ANOVA).
doi:10.1371/journal.pone.0067178.g002
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I and Figure S5A, B).
Collectively, our study identifies an important functional and
regulatory link between NDR1 and the TGFb signaling pathway.
NDR1 suppresses TGFb-induced transcription and cell cycle
arrest, and to overcome this effect, TGFb promotes the
ubiquitination and turnover of NDR1.
Discussion
In this study, we have discovered a critical role for the protein
kinase NDR1 in the regulation of TGFb signaling in proliferating
cells. We have identified NDR1 as a novel interacting protein with
SnoN, a key component of the TGFb signaling pathway. Loss and
gain of function analyses reveal that NDR1 suppresses TGFb-
induced transcription and cell cycle arrest in epithelial cells. NDR1
inhibits the ability of TGFb to induce the phosphorylation and
consequent nuclear accumulation of Smad2, providing the
mechanistic basis for NDR1 regulation of TGFb-induced tran-
scription and cellular responses. Remarkably, we have also found
that TGFb reciprocally regulates NDR1, triggering the degrada-
tion of NDR1. These findings define an intimate link between
NDR1 and TGFb signaling, whereby NDR1 inhibits TGFb-
induced transcription and cell cycle arrest, and to counteract this
effect, TGFb enhances the turnover of NDR1 protein (Figure 7).
The finding that NDR1 antagonizes TGFb-induced cell cycle
arrest in epithelial suggests that cancer cells may employ an
NDR1-dependent mechanisms to evade the tumor suppressive
effect of TGFb. Consistent with this possibility, we have found that
knockdown of NDR1 restores the ability of TGFb to induce cell
cycle arrest in the human breast MDA-MB-231 carcinoma cells,
which are resistant to the TGFb-induced cell cycle arrest (Figure
S6A, B, C). Thus, deregulation of NDR1 control of TGFb
signaling may be relevant in cancer pathogenesis.
The identification of NDR1 as a novel regulator of TGFb-
induced transcription advances our understanding of the mech-
anisms that control TGFb responses. We have found that NDR1
markedly inhibits TGFb-induced cell cycle arrest. In future
studies, it will be interesting to determine whether NDR1
modulates other TGFb responses including epithelial-mesenchy-
mal transition, extracellular remodeling, and cell migration, or
whether NDR1 specifically regulates cell proliferation.
How does NDR1 inhibit TGFb-induced transcription and cell
cycle arrest? We have found that NDR1 strongly inhibits the
phosphorylation and the nuclear accumulation of Smad2. The
inhibition of Smad2 phosphorylation provides a basis for NDR1-
inhibition of TGFb-induced transcription and cell cycle arrest.
Recent studies suggest that the protein kinase lats, which is related
to NDR1, restricts the nuclear accumulation of Smad2 without
affecting its phosphorylation [58]. Thus, NDR1 and lats employ
distinct mechanisms to regulate TGFb signaling. How NDR1
inhibits Smad2 phosphorylation remains to be characterized.
Since the kinase activity of NDR1 is required for its ability to
inhibit Smad2 signaling, it will be critical in future studies to
identify substrates of NDR1 that lead to the inhibition of Smad2
phosphorylation.
The finding that TGFb triggers the degradation of NDR1
proteins suggests that reciprocal negative feedback regulation of
NDR1 and TGFb signaling provides balance in their mutually
opposing effects. Intriguingly, TGFb induces the degradation of
SnoN, which as we have found in this study interacts with NDR1.
The E3 ubiquitin ligases Cdh1-APC, Smurf2, and Arkadia
mediate the TGFb-induced ubiquitination and consequent deg-
radation of SnoN [49,50,59,60,61]. In future studies, it will be
interesting to determine if these E3 ubiquitin ligases or others
induce the ubiquitination of NDR1 in cells upon exposure to
TGFb.
Figure 3. NDR1 represses TGFb-induction of endogenous PAI-
1 gene expression. A. RNA extracts of untreated or TGFb-treated
NMuMG cells transfected with a c o n t r o lR N A ip l a s m i do rt h e
combination of NDR1i-1 and NDR1i-2 RNAi plasmids were subjected
to quantitative RT-PCR to determine the abundance of PAI-1 mRNA,
where GAPDH mRNA was used as an internal control. Data are
presented as the mean+SEM (n=5) of GAPDH-normalized PAI-1 mRNA
abundance relative to untreated control. B. Lysates of NMuMG cells
expressing FLAG-tagged wild type NDR1 (WT) or kinase-inactive NDR1
in which Lysine 118 is mutated to arginine (KR), or vector control were
subjected to immunoblotting using the NDR1 or actin antibody, with
the latter serving as a loading control. C. RNA extracts from untreated
or TGFb-treated NMuMG cells expressing wild type or kinase-inactive
NDR1 or the vector control were subjected to quantitative RT-PCR
analysis of PAI-1 and GAPDH mRNA as described in A. Data are
presented as the mean+SEM (n=3) of relative GAPDH-normalized PAI-
1 mRNA abundance as in A. *, **, or *** indicates significant difference
from the TGFb-treated control at p,0.05, p,0.01, or p,0.001,
respectively (ANOVA).
doi:10.1371/journal.pone.0067178.g003
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PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67178Figure 4. NDR1 suppresses TGFb-repression of cell proliferation. A. Population growth curves of NMuMG cells expressing wild type (WT) or
kinase-inactive (KR) NDR1 or the vector control (2) analyzed using phase-contrast microscopy after one, two or three days of culturing in the absence
(solid lines) or presence (broken lines) of TGFb. Each point is the mean6SEM (n=7) of cell population normalized to cell population seeding. B. The
effect of TGFb on cell population growth curves for NMuMG expressing NDR1 or the vector control as in A was analyzed as the difference of
untreated and TGFb-treated cell populations as a percent of untreated cell counts. Each point is the mean+SEM (n=7) of the percent decrease in
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PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e67178Although we have focused our studies on the identification of
NDR1 as a novel regulator of TGFb signaling in proliferating
cells, our findings may have broader implications for both TGFb
signaling and NDR1. In the developing mammalian nervous
system, TGFb-Smad2 signaling has been implicated in the control
of axon development, whereby Smad2 inhibits axon growth in
granule neurons of the rat cerebellar cortex [62]. In view of our
finding demonstrating that NDR1 inhibits Smad2 signaling, it will
be interesting to determine whether NDR1 promotes axon growth
in mammalian neurons. Conversely, recent studies have revealed
that NDR1 controls the development of dendrites and synapses in
mouse hippocampal neurons [46]. Our finding that TGFb induces
the degradation of NDR1 raises the interesting question of
whether TGFb might influence these aspects of neuronal
morphogenesis.
Our findings have implications beyond cellular development
and homeostasis. Since loss of responsiveness to TGFb-induced
cell cycle arrest contributes to tumorigenesis [10,11,12,13,14], the
identification of a novel role for NDR1 in TGFb signaling suggests
that NDR1 may also influence tumor initiation. Notably, NDR1 is
upregulated in lung and mammary carcinomas [47,48], raising the
possibility that NDR1 might contribute to loss of TGFb
responsiveness in these tumors. Thus, our study raises the potential
for NDR1 as a target for drug discovery in cancer biology.
Materials and Methods
Plasmids
A pCaGiP vector was used to generate FLAG, HA double
epitope-tagged SnoN or FLAG epitope-tagged NDR1 stable
expression constructs, where a bicistronic transcript containing an
internal ribosomal entry site (IRES) encoded the puromycin
resistance marker and the protein of interest [39,63,64]. FLAG,
HA-tagged SnoN containing nucleotides to express FLAG,
Tobacco Etched Virus (TEV) protease site (ENLYFQG), and
HA peptides upstream of the SnoN cDNA was generated using a
polymerase chain reaction (PCR)-based cloning approach. Ex-
pression vectors to express fusion proteins of Renillla luciferase
(Rluc) with wild type or deletion mutant SnoN were generated by
PCR-based amplification and subcloning of the Rluc cDNA
upstream of SnoN cDNA in CMV-based (pCMV5B) SnoN-
expression vectors [37,49,50,65]. The NDR1 cDNA product of
PCR amplification of epithelial cell-derived polyA-cDNA using
NDR1gene-specific oligonucleotides was used to generate HA-
and FLAG-tagged NDR1 expression vectors (pCMV5B and
pCaGiP). Constructs expressing Rluc in fusion with wild type or
deletion mutant NDR1 were generated as described for Rluc-
SnoN. NDR1 and NDR2 RNA interference (RNAi) plasmids were
constructed using the pU6/CMV/enhanced green fluorescent
protein (GFP) expression control vector, with NDR1 or NDR2
shorthairpin RNAs (shRNAs), and GFP under the control of U6
and CMV promoters, respectively [40]. Two shRNAs-expressing
constructs were generated to target distinct regions in each of
NDR1 and NDR2 mRNAs as follows: NDR1i-1, 59GCAACCT-
TATCGCTCAACAT39, NDR1i-2, 59GGCAGA-
population growth by TGFb. C. Representative fluorescence microscopy images of untreated or 48h-TGFb-treated NMuMG cells expressing wild type
or kinase-inactive NDR1 or the vector control that were incubated for 1 h with bromodeoxyuridine (BrdU) and subjected to indirect
immunofluorescence using the BrdU antibody and a Cy2-conjugated secondary antibody (green), and labeling with the DNA Hoechst dye (blue) D.
For each cell type as in C, percent reduction of BrdU-labeled cells in response to TGFb was quantified as in B. Data are presented as the mean+SEM
(n=3) of the percent reduction in BrdU incorporation in cells in response to TGFb. E. Representative fluorescence images of GFP-expressing (green)
and DNA dye (Hoechst) (blue)-labeled NMuMG cells transfected with control RNAi plasmid or the combination of NDR1i-1 and NDR1i-2 (NDR1i) RNAi
plasmids alone or together with the combination of NDR2i-1 and NDR2i-2 RNAi (NDRi) plasmids, and incubated one day post transfection with 0, 5,
20 and 100 pM TGFb for 36 h. F. A target activation algorithm accompanying the Cellomics KSR instrument used to capture images including those
shown in E was used to determine population growth of GFP-positive cells in 96 well plates. For each experiment, triplicate average population
growth of GFP-positive cells was plotted versus TGFb concentration and fitted using log transformation to obtain the effective concentration of TGFb
leading to 50% reduction of population growth of GFP-expressing cells (EC50). Data are presented as the mean+SEM of EC50 values expressed
relative to the NMuMG cells transfected with the vector control from six (- and NDRi) or five (NDR1i) independent experiments. The width of each
fluorescence micrograph in C and E corresponds to 330 mM. **, or *** indicates significant difference from the control at p,0.01, or p,0.001,
respectively (ANOVA).
doi:10.1371/journal.pone.0067178.g004
Figure 5. NDR1 impairs TGFb-phosphorylation of Smad2. A.
Lysates of untreated or 48h-TGFb-incubated NMuMG cells transfected
with an expression plasmid encoding wild type or kinase-inactive NDR1,
or transfected with the vector control were subjected to immunoblot-
ting using an antibody that recognizes Smad2 when phosphorylated
specifically at the TGFb-induced sites (pSmad2) or an antibody that
recognizes Smad2 regardless of its phosphorylation status (Smad2) or
with an actin antibody, the latter serving as a loading control. B. Actin-
normalized TGFb-phosphorylated Smad2 was expressed relative to the
actin-normalized total Smad2. Data are presented as the mean+SEM
(n=3) ratio of TGFb-phosphorylated Smad2 to total Smad2. Statistical
significance between TGFb-induced phosphorylation of Smad2 in the
vector control cells and each of the wild type and kinase-inactive NDR1-
expressing cells is indicated (ANOVA).
doi:10.1371/journal.pone.0067178.g005
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PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e67178Figure 6. TGFb signaling promotes NDR1 turnover. A. Lysates of untreated or 48h-TGFb-treated NMuMG cells in the absence or presence of
the TGFb type I receptor kinase inhibitor SB431542 (KI) were subjected to immunoblotting with the NDR1 or actin antibody. B. Protein abundance of
NDR1 and actin in immunoblots, including those shown in A, were quantified and percent reduction of NDR1 (normalized to actin) in response to
TGFb was analyzed. Data are presented as the mean+SEM (n=4) of percent decrease in protein abundance of NDR1 in NMuMG cells in response to
TGFb. TGFb treatment decreased the protein abundance of NDR1 in NMuMG cells. C. TGFb does not repress NDR1 mRNA expression. RNA extracts
from untreated or 48h-TGFb-treated NMuMG cells were analyzed by quantitative RT-PCR for NDR1 and GAPDH mRNA abundance. Data are presented
as the mean+SEM (n=3) of relative mRNA abundance of NDR1 in NMuMG cells. TGFb did not reduce relative abundance of NDR1 mRNA. Significant
NDR1 and TGFb Signaling Are Functionally Linked
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e67178CAGTTTGTGGGT TGT39, NDR2i-1, 59GGAGGTGACAT-
GATGACATT39, and NDR2i-2, 59GCAGACTG GTTACAA-
CAAATT39. All constructs were verified by restriction digests and
DNA sequencing analysis (University of Calgary Core Sequencing
Facility).
Cell Cultures and Transfections
The human keratinocyte HaCaT [66], embryonic kidney 293T
[67,68], and mouse mammary gland epithelial NMuMG
[69,70,71] cells were obtained from ATCC and maintained in
appropriate growth conditions [39,40,63,72]. The human breast
carcinoma MDA-MB-231 cells, a generous gift from Dr. Frank
Jirik, were maintained in Dulbecco’s Modified Eagle Medium
containing 10% fetal bovine serum [73,74]. 293T cells were
transfected using the calcium phosphate method [40]. HaCaT
cells were transiently transfected using Fugene (Roche), TransIT-
LT1 reagent (Mirus), or Lipofectamine-LTX (Invitrogen) accord-
ing to the manufacturer’s instructions. HaCaT cells were
transfected with the pCAGiP vector (vector control) or one
encoding the FLAG, HA-SnoN using Lipofectin (Invitrogen) and
incubation in 0.45 mg/ml puromycin (Invitrogen)-containing
medium for selection of control vector or SnoN stably expressing
cells. A similar strategy was used to generate control and FLAG-
NDR1 expressing NMuMG cells with the exception of using
2 mg/ml puromycin. MDA-MB-231 were transfected using Lipo-
fectamin and plus reagents (Invitrogen).
Immunoprecipitations, Immunoblottings, and TAP
Cells were lysed in TNE-based buffer-containing 0.5% Triton
X-100, protease and phosphatase inhibitors, and lysates were
cleared by centrifugation and subjected to protein concentration
determination using the Bradford protein assay (BioRad)
[39,40,63,75]. For interaction studies, equivalent amounts of
protein, representing a maximum of approximately 90% of total
protein content per sample, were subjected to immunoprecipita-
tions using appropriate antibodies. Immunoprecipitates and
aliquots of the lysates were subjected to immunoblottings or
Renilla luciferase assays using the Renilla luciferase kit (Promega)
and the Orion II luminometer (Berthold Detection Systems)
detection system. Immunoprecipitates-containing Rluc-fusion
proteins (or Rluc protein alone) were resuspended in TNE buffer
containing 0.1% Triton X-100 prior to measuring any associated
luciferase activity [53]. Antibodies used in the immunoprecipita-
tions and immunoblottings included rabbit anti-SnoN (H317,
Santa Cruz), mouse anti-Flag (M2, Sigma), mouse anti-Myc
(9E10, Covance), mouse anti-HA (16B12, Covance), rabbit anti-
Actin (Sigma), mouse anti-NDR1 (2G8–1F3, Abnova), rabbit anti-
NDR1 (H100, Santa Cruz), mouse anti-Smad2/3 (BD-Transduc-
tion laboratories), rabbit anti-phospho (Ser465/467) Smad2
(Calbiochem), and horseradish peroxidase-conjugated anti-mouse
and anti-rabbit IgG antibodies (GE healthcare). Immunoblotting-
generated enhanced chemiluminescence signals were visualized
and quantified using a Versadoc 5000 Imager (Bio-Rad) and
Quantity One software, respectively [39,40,63,75]. For tandem
affinity purification (TAP) experiments, lysates of FLAG, HA-
SnoN-expressing HaCaT cells or vector control-transfected
HaCaT cells were subjected to immunoprecipitation using anti-
FLAGH M2 antibody affinity gel (Sigma), elution of immunocom-
plexes by treatment with TEV enzyme, immunoprecipitation of
the eluate with anti-HA affinity matrix (Roche), and partial
separation of immunoprecipitates by SDS-PAGE. Processing and
analysis of colloidal Coomassie-stained gel slices was performed at
the Southern Alberta Mass Spectrometry (SAMS) Centre for
Proteomics by LC-MS/MS [51,52].
Luciferase Reporter Assays
HaCaT and NMuMG cells were seeded at 2.5 to 3.5610
4 cells/
well in 24-well plates. Cells were co-transfected with the 3TP-
Firefly luciferase reporter constructs, the CMV-b-galactosidase or
pR-TK Renilla luciferase internal control reporter constructs,
together with a control vector or one encoding an NDR1 protein,
or with a control or NDR1 RNAi vector, incubated for 16 to 18 h
in 0.2% fetal bovine serum-containing medium in the absence or
presence of 100 pM TGFb (R & D Systems, Minneapolis, MN),
lysed and subjected to single or dual luciferase activity assays
[39,40,63,72,75], with each experimental condition carried out in
triplicates. Each replicate’s arbitrary Firefly luciferase activity, in
relative light units, was normalized to its b-galactosidase or Renilla-
luciferase activity, to control for variations in transfection
efficiency.
differences are indicated in B and C as determined by unpaired, two-tailed t-test. D. Lysates of NMuMG cells left untreated or incubated with 10 mg/
ml cycloheximide for different times, alone or together with 100 pM TGFb, were subjected to immunoblotting using the NDR1 or actin antibody. E.
Protein abundance of NDR1 in immunoblots, including the one shown in Figure 6D, were quantified and normalized to actin. Data are presented as
the mean6SEM (n=3) of normalized protein abundance of NDR1 expressed relative to that at time 0 for the respective minus or plus TGFb group.
Data interpolation indicated that NDR1’s half-life was greater than 16 h. TGFb reduced NDR1’s half-life to approximately 9 h. F. Lysates of untreated
or 24 h-TGFb-preincubated NMuMG cells followed by exposure to cycloheximide for different time points, were subjected to immunoblotting using
NDR1 or actin antibody. G. Protein abundance of NDR1 in immunoblots as described and including the one shown in Figure 6F was quantified as
described in E. Data are presented as the mean6SEM (n=4) of relative NDR1 levels. TGFb reduced the half-life of NDR1 from greater than 16 h to
approximately 2.5 h. H. TGFb signaling enhances the ubiquitination of NDR1. Lysates of 293T cells expressing FLAG-NDR1, HA-ubiquitin, and
constitutively active TGFb type I receptor, were subjected to immunoprecipitation using the FLAG antibody, followed by immunoblotting with the
HA or NDR1 antibody. Cell lysates were also immunoblotted with the FLAG or actin antibody. HC refers to the heavy chain of the FLAG antibody. I.
Lysates of 293T cells transfected with FLAG-NDR1 alone or together with constitutively active TGFb type I receptor and treated without or with
0.5 mM MG132 (Sigma) for 7 hours were subjected to immunoblotting with the FLAG or actin antibody. *, **, or *** in E and G indicates significant
difference from respective control at P,0.05, p,0.01, or p,0.001, respectively (ANOVA). # indicates significant difference from control (p,0.05,
unpaired, one tailed t-test).
doi:10.1371/journal.pone.0067178.g006
Figure 7. A schematic model showing that SnoN and NDR1
interact, and that NDR1 and TGFb reciprocally inhibit each
other in epithelial cells.
doi:10.1371/journal.pone.0067178.g007
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DNase-treated TRIzol (Gibco)-extracted RNA from NMuMG
cells cultured in the absence or presence TGFb was reverse
transcribed using SuperScript II transcriptase (Invitrogen) and
oligo-(dT)12–18 (Amersham Biosciences) [40,63,75,76]. The polyA-
cDNAs were subjected to quantitative PCR using gene-specific
primers for Plasminogen Activator Inhibitor 1 (forward-
59TCTCAGAGGTGGAAAGAGCCAG39, reverse-59TGAAG-
TAGAGGGCATTCACCAGC39), NDR1 (forward-
59ATTTGGTGAGGTACGGCTTG39 and reverse-59CAGG-
CAGGAACTCCA TGATT39), and the house-keeping gene
glyceraldehyde-3-phosphate dehydrogenase (forward-59TCAA-
CAGCAACTCCCACTCTTCCA39 and reverse-59AC-
CCTGTTGCTGTAGCCGTATTC A39) using a 2X Sybr Green
Mix (BioRad) and Rotor-Gene Thermocycler (Corbett Research).
The specificity of the products was confirmed using the melt curve
method. Data were analyzed and expressed as described [75].
Microscopy and Cell Proliferation Assays
For fluorescence microscopy experiments, NMuMG cells left
untreated or incubated with TGFb for two days were formalde-
hyde-fixed, and incubated with DNA dye bisbenzimide (Hoechst)
(Invitrogen). For indirect Smad2/3 immunofluorescence, untreat-
ed or TGFb-treated NMuMG cells were incubated with a mouse
Smad2/3 antibody, and a Cy3-labelled anti-mouse antibody
(Jackson Laboratories) in the presence of the DNA dye Hoechst.
Images of cells were captured using a Kinetic Scan Reader (KSR)
(Cellomics, Inc., Pittsburgh, PA) equipped with a Carl Zeiss Axiom
x microscope and a charge-coupled device (CCD) digital camera
[39,63]. Bromodeoxyuridine (BrdU) assays were carried out using
a BrdU assay kit (Roche), fluorescence images were captured using
fluorescence microscopy, and data were generated using the
Target Activation Bio-Application of the Cellomics KSR [39]. For
cell growth rates analyses, cells were grown for one, two or three
days in the presence or absence of 100 pM TGFb, and counted
using a haemocytometer prior to and at each day during
treatment. Alternatively, population cell growth was determined
based on nuclei counts in fixed cells stained with the DNA dye
Hoechst. Cell counts were normalized to cell numbers before
treatment, and replicate values were averaged. For RNAi assays,
NMuMG or MDA-MB-231 cells were transfected with GFP-
expressing plasmids containing an RNAi control vector, or the
NDR1 shRNAs alone or together with NDR2 shRNA expressing
vectors as described in the legends of Figure 4, Figure S3, and
Figure S6. Untreated or TGFb-incubated NMuMG or MDA-MB-
231 cells were fixed and incubated with the DNA dye Hoechst
36 h after ligand treatment. Cells were identified by GFP (green)
and nuclei (Hoechst) (blue) fluorescence signals, and the number of
GFP-positive cells was assayed using the Target Activation Bio-
Application of the Cellomics KSR instrument. Data were analyzed
as described in figure legends.
Statistical Analysis
Data were subjected to Analysis of Variance (ANOV) or student
t-test as indicated in the figure legends with significant difference
set at p,0.05.
Supporting Information
Figure S1 Related to Figure 1. A. Lysates of 293T cells
expressing Renilla luciferase (Rluc), alone, or as fusion with SnoN
(Rluc-SnoN) were subjected to immunoprecipitation using the
NDR1 antibody or IgG immunoglobulins, as a negative control,
followed by analysis of immunoprecipitates by luciferase assays
(90%) or immunoblotting (10%) with NDR1 antibody (data not
shown). Cell lysates were also analyzed by luciferase assays and
immunoblotting using NDR1 or actin antibody (data not shown).
Endogenous NDR1-associated Rluc or Rluc-SnoN luciferase
(IgG-subtracted) were normalized to Rluc or Rluc-SnoN,
respectively, and endogenous NDR1 expression. The data are
presented as the mean +SEM (n=3) of NDR1-associated Rluc
activity relative to Rluc activity associated with NDR1 in the case
of the Rluc control. Rluc-SnoN associated robustly with
endogenous NDR1. B. Lysates of 293T cells expressing Rluc or
Rluc-NDR1 were subjected to immunoprecipitation using a SnoN
antibody or IgG immunoglobulins, as a negative control, followed
by analysis of the immunoprecipitates by luciferase assays (90%) or
immunoblotting (10%) with SnoN antibody (data not shown). Cell
lysates were also subjected to luciferase assays or immunoblotting
with SnoN or actin antibody (data not shown). Endogenous SnoN-
associated Rluc or Rluc-NDR1 activity was determined as in A.
Data are presented as the mean+SEM (n=4) of SnoN-associated
Rluc activity relative to Rluc activity associated with SnoN in the
case of the Rluc control. Rluc-NDR1 interacted strongly with
endogenous SnoN. C. Lysates of untreated or TGFb-treated 293T
cells were subjected to immunoprecipitation using NDR1 antibody
or IgG immunoglobulins, as a negative control, followed by
immunoblotting with the SnoN or NDR1 antibody. Cell lysates
were also subjected to immunoblotting with the SnoN, NDR1 or
actin antibody with the latter serving as a loading control. **** in
A and B indicates significant difference from the control
(p,0.0001, t-test).
(TIF)
Figure S2 Related to Figure 2. A. Lysates of 293T cells
expressing HA-NDR1 in the presence of the control RNAi vector,
or NDR1 RNAi NDR1i-1 or NDR1i-2 plasmid were subjected to
immunoblotting using the HA or actin antibody, with the latter to
serve as a loading control. NDR1i-1 or NDR1i-2 induced 80 to 90
percent knockdown of NDR1. B. Lysates of NMuMG cells
transfected with increasing concentrations of a plasmid expressing
HA-NDR1 together with the TGFb-responsive 3TP-luciferase
reporter and a transfection efficiency vector as described in
Figure 2C, were subjected to immunoblotting using the HA or
actin antibody. Images in A and B are representative blots from
experiments that were repeated at least two independent times.
(TIF)
Figure S3 Related to Figure 4. A. Population growth of
NMuMG cells expressing wild type (WT) or kinase-inactive (KR)
NDR1, or control vector (2) after culturing for one, two, or three
days in the absence or presence of 100 pM TGFb was determined
by subjecting DNA dye (Hoechst)-labeled NMuMG cells to
fluorescence microscopy and data analysis using the Cellomics
KSR platform and Target Activation algorithm. Percent decrease
in population growth of NMuMG cells by TGFb was quantified as
described in Figure 4B. Data are presented as the mean+SEM of
percent reduction of population growth of NMuMG cells by
TGFb from three (day 1 and day 3) or five (day 2) independent
experiments. ** or *** indicates significant difference from the
respective control within each day at p,0.01, or P,0.001,
respectively (ANOVA). B. Representative fluorescence images of
NMuMG cells one day post transfection with control RNAi,
NDR1i or NDRi plasmids as described Figure 4E, where the DNA
dye Hoechst (blue) and GFP (green)-induced signals indicate total
NMuMG cells and transfected NMuMG cells, respectively.
Analysis of the GFP-labeled cells as compared to total cells using
the target activation algorithm indicated approximately 50 percent
transfection efficiency for all three sets of transfections. The width
NDR1 and TGFb Signaling Are Functionally Linked
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e67178of each micrograph corresponds to 330 mm. C. For each
experiment including the one shown in Figure 4E, triplicate
average of GFP-positive cells at each TGFb concentration was
determined. Data are presented as the mean6SEM of relative
GFP-positive cell numbers from six (control and NDRi) or five
(NDR1i) independent experiments.
(TIF)
Figure S4 Related to Figure 5. Representative images of
untreated or TGFb-treated NMuMG cells expressing wild type or
kinase-inactive NDR1 or vector control that were subjected to
indirect immunofluorescence using the Smad2 antibody and a
Cy3-secondary antibody (red) and labeling with the DNA Hoechst
dye (blue), and scanned by fluorescence microscopy. The width of
each micrograph corresponds to 330 mm.
(TIF)
Figure S5 Related to Figure 6. A. Lysates of 293T cells
coexpressing FLAG-NDR1 and HA-ubiquitin alone or together
with the constitutively active TGFb type I receptor, harboring a
mutation in Threonine 204 to aspartate, were subjected to
immunoprecipitation using the FLAG antibody followed by
immunoblotting with the HA or NDR1 antibody as described in
Figure 6H. Ubiquitin-conjugated NDR1 protein species as
indicated in and including the protein species in Figure 6H
immunoblots were quantified and normalized to NDR1 levels in
the immunoprecipitates. Data are presented as the mean+SEM
(n=3) of ubiquitin-conjugated NDR1 species relative to the
ubiquitinated NDR1 in cells coexpressing NDR1 and ubiquitin.
Significant difference between the two groups was determined
using unpaired, two-tailed t-test. B. Lysates of untreated or
MG132-treated 293T cells expressing FLAG-NDR1 alone or
together with constitutively active receptor were subjected to
FLAG and actin immunoblotting as described in Figure 6I. NDR1
protein species as indicated and including the protein species in
Figure 6I were quantified and normalized to respective actin. Data
are presented as the mean+SEM (n=6) of NDR1 relative to
NDR1 in cells expressing NDR1 alone and left in the absence of
MG132. *** indicates significant difference from the control
(p,0.001, ANOVA).
(TIF)
Figure S6 NDR1 knockdown restores the ability of
TGFb to inhibit cell proliferation in the breast MDA-
MB-231 carcinoma cells. A. Lysates of MDA-MB-231
transfected with a control or NDR1 RNAi plasmids, were
subjected to immunoblotting with an NDR1 or actin antibody.
Values shown below lanes 1 and 2 represent actin-normalized
NDR1 level expressed relative to the actin-normalized NDR1 level
in the RNAi control vector transfected cells. B. GFP-expressing
and DNA-Hoechst-labeled MDA-MB-231 cells transfected as in A
and incubated one day post transfection with 0, 25, 100, or
400 pM TGFb for 72 h were imaged and quantified by
fluorescence microscopy and the target activation bio-application,
respectively, using the Cellomics KSR as in Figure 4 and Figure
S3. Untreated or TGFb-treated cells were seeded in triplicates or
quadruplicates in a 96-well plate, and population growth of GFP-
positive cells were averaged. Data are presented as the mean+-
SEM of average population growth of GFP-positive MDA-MB-
231 cells from five independent experiments expressed relative to
the untreated control. C. MDA-MB-231 cells transfected as in A
and left untreated or treated with 400 pM TGFb were incubated
for the last hour with bromodeoxyuridine, and subjected to
immunocytochemistry using a BrdU antibody, fluorescence
microscopy and analysis as described in Figure 4. Target
activation bioapplication was used to quantify ratio of GFP-
expressing BrdU labeled cells, and averages of replicates quantified
as in B. Data are presented as the mean+SEM of GFP-expressing
BrdU-positive cells from 5 independent experiments. ** or ***
indicates significant difference from the control at p,0.01, or
p,0.001, respectively (ANOVA).
(TIF)
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